Showing session: reset
Spotlight on Proffered Papers 3
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Geraldine O'Sullivan Coyne
National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Permission not
granted for presentation
Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
Anthony W. Tolcher
NEXT Oncology, San Antonio, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Christopher J Schulze
Revolution Medicines, Redwood City, CA, United States